Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.
暂无分享,去创建一个
D. Atar | T. Kvien | P. Mowinckel | M. Fagerhol | S. Provan | K. Angel
[1] W. Ghali,et al. Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis , 2011, Arthritis care & research.
[2] Yasmin,et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ , 2010, European heart journal.
[3] D. Atar,et al. Tumor Necrosis Factor-&agr; Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies: A Controlled Study , 2010, Hypertension.
[4] D. Symmons,et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.
[5] P. Libby,et al. Myeloid-Related Protein-8/14 Is Critical for the Biological Response to Vascular Injury , 2009, Circulation.
[6] A. Ferrante,et al. Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis , 2009, Rheumatology International.
[7] P. Sidiropoulos,et al. Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients , 2009, Scandinavian journal of rheumatology.
[8] S. Oakley,et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.
[9] G. Baron,et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. , 2008, Rheumatology.
[10] K. Walley,et al. S100A8 and S100A9 Mediate Endotoxin-Induced Cardiomyocyte Dysfunction via the Receptor for Advanced Glycation End Products , 2008, Circulation research.
[11] W. Nacken,et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.
[12] M. Vitale,et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. , 2007, Rheumatology.
[13] M. Hersberger,et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. , 2007, European heart journal.
[14] T. Tuomainen,et al. Augmentation index and carotid intima–media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein , 2007, Journal of hypertension.
[15] E. Vicaut,et al. Mannheim Carotid Intima-Media Thickness Consensus (2004–2006) , 2006, Cerebrovascular Diseases.
[16] H. Struijker‐Boudier,et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. , 2006, European heart journal.
[17] Michiel L Bots,et al. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies , 2006, Current medical research and opinion.
[18] Yasmin,et al. Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti–Tumor Necrosis Factor-&agr; Therapy , 2006, Circulation.
[19] J. Staessen,et al. Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials , 2006, Stroke.
[20] P. Libby,et al. Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events , 2006, Circulation.
[21] Javier Martín,et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[22] G. McColl,et al. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. , 2005, Rheumatology.
[23] D. Foell,et al. Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis , 2005, The Journal of pathology.
[24] James G Terry,et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors , 2005, Current controlled trials in cardiovascular medicine.
[25] P. T. Larsson,et al. Circulating markers of inflammation are related to carotid artery atherosclerosis. , 2005, International angiology : a journal of the International Union of Angiology.
[26] A. Gnasso,et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. , 2004, Atherosclerosis.
[27] M. Bots,et al. Aortic stiffness and carotid intima‐media thickness: two independent markers of subclinical vascular damage in young adults? , 2003, European journal of clinical investigation.
[28] R. Asmar,et al. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT , 2003, Blood pressure monitoring.
[29] R. Reneman,et al. An integrated system for the non-invasive assessment of vessel wall and hemodynamic properties of large arteries by means of ultrasound. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.
[30] R. Jonsson,et al. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. , 1994, The Journal of rheumatology.
[31] E. Lingaas,et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin , 1990, The Lancet.